Inogen (INGN) Corporate presentation summary

Strategic transformation and market expansion

• Transitioning from a single-product oxygen company to a diversified respiratory care platform, now serving COPD, bronchiectasis, and sleep apnea markets with an estimated 70 million U.S. patients.

• Portfolio expansion includes new launches in stationary oxygen concentrators, airway clearance devices, and CPAP masks, increasing total addressable market to $3.4B.

• Leveraging established brand, distribution, and physician trust to enter adjacent markets with significant patient overlap.

• Focused on innovation with at least one new product launch per year and digital solutions to enhance patient engagement and outcomes.

Financial performance and turnaround

• Achieved positive adjusted EBITDA in FY25 for the first time since 2021, with a 107% improvement from FY23 to FY25.

• Revenue grew from $316M in 2023 to $349M in 2025, with mid-single digit growth over the last two years.

• Gross margin improved by 10% and operating loss reduced by 72% over the same period.

• Maintained a strong balance sheet with $121M in cash and no debt as of year-end 2025.

Strategic priorities and capital allocation

• Prioritizing top-line growth, profitability, and innovation pipeline expansion.

• Investing in core business and new product launches, while executing a $30M share repurchase program.

• Evaluating disciplined M&A opportunities to accelerate growth and profitability.